SCHEMBL6399780

SCHEMBL6399780

CCC(c1cccc(O)c1)C(O)c1cc(O)ccc1P(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.45
SLC22A1 O15245 1/20 0.45
ADRA1A P35348 3/20 0.39
ADRB1 P08588 2/20 0.39
MIF P14174 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2B P41595 1/20 0.39
HIF1A Q16665 4/20 0.39
LMNA P02545 4/20 0.39
GALR3 O60755 1/20 0.39
DRD1 P21728 2/20 0.38
DRD3 P35462 2/20 0.38
SLC6A3 Q01959 2/20 0.38
ADRB2 P07550 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRB3 P13945 1/20 0.38
TSHR P16473 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396452 0.90 OPRM1 (0.45) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6394500 0.88 ESR1 (0.49) OPRM1ADRA1AHIF1ALMNADRD1
SCHEMBL6395103 0.83 ADRB1 (0.45) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6399774 0.81 OPRM1 (0.42) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6397848 0.81 OPRM1 (0.42) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6401542 0.81 SLC22A1 (0.44) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6403263 0.80 SLC22A1 (0.43) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6396445 0.79 OPRM1 (0.42) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6395967 0.79 OPRM1 (0.42) OPRM1SLC22A1ADRA1AADRB1MIF
SCHEMBL6398725 0.77 ESR1 (0.49) OPRM1ADRA1ALMNADRD1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 OPRM1 4522/4885SLC22A1 50/4885ADRA1A 2552/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 OPRM1 4563/4885SLC22A1 50/4885ADRA1A 2707/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 OPRM1 4522/4885SLC22A1 50/4885ADRA1A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.